Please use this identifier to cite or link to this item: 10.3389/fped.2021.532489
Title: Invasive pneumococcal disease in Latvia in PCV10 vaccination era, 2012-2018
Authors: Savrasova, Larisa
Krūmiņa, Angelika
Zeltiņa, Indra
Villeruša, Anita
Grope, Ilze
Vīksna, Ludmila
Dimiņa, Elīna
Balasegaram, Sooria
Čupeca, Hedija
Rīga Stradiņš University
Department of Infectology
Department of Public Health and Epidemiology
Department of Paediatrics
Keywords: Invasive pneumococcal disease;Vaccination;3.2 Clinical medicine;3.3 Health sciences;1.1. Scientific article indexed in Web of Science and/or Scopus database;SDG 3 - Good Health and Well-being
Issue Date: 7-Oct-2021
Citation: Savrasova , L , Krūmiņa , A , Zeltiņa , I , Villeruša , A , Grope , I , Vīksna , L , Dimiņa , E , Balasegaram , S & Čupeca , H 2021 , ' Invasive pneumococcal disease in Latvia in PCV10 vaccination era, 2012-2018 ' , Frontiers in Pediatrics , vol. 9 , 532489 . https://doi.org/10.3389/fped.2021.532489
Abstract: In 2010 in Latvia, invasive pneumococcal disease (IPD) became a cause for concern and vaccination of infants with four doses of 7–valent pneumococcal conjugate vaccine (PCV7) commenced. In 2012, 10–valent pneumococcal conjugate vaccine (PCV10) (three doses at 2, 4, and 12–15 month of age) vaccination was introduced. We described incidence and serotype distribution of IPD in Latvia and investigated serotypes associated with death from IPD based on surveillance data. Adult vaccination against pneumococcal infection is not included in the national immunization program. Laboratory confirmed IPD cases are passively notified to the Center for Disease Prevention and Control of Latvia (CDPC) by laboratories and clinicians. We calculated incidence by age, sex, case fatality, and trend in serotypes by conducting a retrospective population-based cross-sectional study based on national IPD surveillance data. From 2012 to 2018 466 cases of IPD were reported. The highest notified incidence was in 2015 at 4.4/100,000, which fell to 3.9 in 2018. The highest mean annual IPD incidence was in infants (4.8) and in the elderly (6.0). PCV10 vaccine serotypes were the most prevalent in IPD cases up to 2015 with a decreasing trend from 50% (20/40) in 2012 to 19% (14/74) in 2018 (chi2 test for trend of odds = 0.000). PCV23nonPCV13 vaccine serotypes had an increasing trend and rose from 18% (7/40) to 34% (25/74) (chi2 test for trend of odds = 0.000). Non-Vaccine serotypes had an increasing trend and rose from 13% (5/40) to 27% (20/74) (chi2 test for trend of odds = 0.038). Reported total case fatality was 19% (87/466). The highest, at 36% (20/56), was reported in 2013. After adjusting for age, Streptococcus pneumoniae serotype 3 was associated with death from IPD (adjusted OR 2.3 95%CI 1.25–4.12 p 0.007). Surveillance data indicate evidence of serotype replacement with an increasing trend of serotype 19A and PPV23nonPCV13 and Non-Vaccine serotypes. Serotype 3 and age were associated with fatal IPD outcome. Further studies of S. pneumoniae carriage would be useful in providing more evidence to characterize serotypes' circulation.
Description: Funding Information: This work was supported by the Hepatologu asociacija. Publisher Copyright: © Copyright © 2021 Savrasova, Krumina, Cupeca, Zeltina, Villerusha, Grope, Viksna, Dimina and Balasegaram.
DOI: 10.3389/fped.2021.532489
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:
File SizeFormat 
Invasive_Pneumococcal_Disease.pdf784 kBAdobe PDFView/Openopen_acces_unlocked


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.